ELVN
Enliven Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1.15M | $52.90M | n/a | n/a |
| Q2 2026 | 80 | +13 | 36.53M | $1.84B | +16 | −4 |
| Q1 2026 | 71 | +9 | 24.13M | $927.49M | +16 | −7 |
| Q4 2025 | 62 | -3 | 26.77M | $412.32M | n/a | −3 |
| Q3 2025 | 17 | 0 | 20.16M | $412.75M | n/a | n/a |
| Q2 2025 | 14 | +1 | 19.32M | $387.50M | +1 | n/a |
| Q1 2025 | 10 | +1 | 3.57M | $70.26M | +2 | −1 |
| Q4 2024 | 9 | 0 | 4.15M | $93.48M | n/a | n/a |
| Q3 2024 | 8 | +1 | 3.55M | $90.68M | +1 | n/a |
| Q2 2024 | 7 | n/a | 4.08M | $95.46M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 2.31M | n/a | $53.93M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 840.00K | n/a | $19.63M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 682.39K | n/a | $15.95M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 192.10K | n/a | $4.49M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 33.90K | n/a | $792,313 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 17.24K | n/a | $402,829 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 11.21K | n/a | $262,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 2.40K shares, $94,276 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.02K sh · $231,546
Officer · 5.00K sh · $192,342
Director · 13.00K sh · $606,719
Officer · 2.19K sh · $111,270
Officer · 289 sh · $14,881
Officer · 2.92K sh · $145,891
Officer · 1.84K sh · $93,507
Officer · 240 sh · $12,356
Officer · 3.54K sh · $176,851
Officer · 1.39K sh · $82,383
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
9.5% of class · View original SEC filing ↗
10.9% of class · View original SEC filing ↗